Xin Wei Wang
Overview
Explore the profile of Xin Wei Wang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
171
Citations
11790
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Benmebarek M, Oguz C, Seifert M, Ruf B, Myojin Y, Bauer K, et al.
Immunity
. 2025 Mar;
PMID: 40088889
Anti-vascular endothelial growth factor (VEGF) treatment has shown clinical activity together with immune checkpoint blockade (ICB), but the exact mechanism is not known. We show that VEGF blockade in combination...
2.
Shiode Y, Kodama T, Sato Y, Takahashi R, Matsumae T, Shirai K, et al.
Biomark Res
. 2025 Mar;
13(1):37.
PMID: 40038575
Background: Hepatocellular carcinoma (HCC) can be classified into several subtypes based on molecular traits, aiding in prognostic stratification. The subtype with a poor prognosis is often associated with stem/progenitor features....
3.
Myojin Y, Babaei S, Trehan R, Hoffman C, Kedei N, Ruf B, et al.
Gut
. 2025 Feb;
PMID: 39965889
Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality. The combination of tremelimumab and durvalumab is now a standard treatment option for advanced HCC. Objective: To study immune...
4.
Watling C, Hua X, Petrick J, Zhang X, Do W, Wang L, et al.
Sci Rep
. 2025 Feb;
15(1):5450.
PMID: 39953193
Recently, studies have reported that pan-viral serology signatures may be predictive for liver cancer development. However, whether these same findings are observed for prospective studies has not been previously investigated....
5.
Ma L, Li C, Wang X
Annu Rev Pathol
. 2025 Jan;
20(1):169-192.
PMID: 39854188
The development of hepatocellular carcinoma (HCC) involves an intricate interplay among various cell types within the liver. Unraveling the orchestration of these cells, particularly in the context of various etiologies,...
6.
Putatunda V, Jusakul A, Roberts L, Wang X
Am J Pathol
. 2024 Nov;
195(3):362-377.
PMID: 39532242
Cholangiocarcinoma (CCA) is an aggressive and heterogeneous malignancy of the biliary tree that carries a poor prognosis. Multiple features at the genetic, epigenetic, and microenvironmental levels have been identified to...
7.
Yang X, Bhowmick K, Rao S, Xiang X, Ohshiro K, Amdur R, et al.
Cell Rep
. 2024 Sep;
43(9):114676.
PMID: 39217614
Obesity and fatty liver diseases-metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH)-affect over one-third of the global population and are exacerbated in individuals with reduced functional aldehyde...
8.
Kajornsrichon W, Chaisaingmongkol J, Pomyen Y, Tit-Oon P, Wang X, Ruchirawat M, et al.
Sci Rep
. 2024 Aug;
14(1):20012.
PMID: 39198554
Intrahepatic cholangiocarcinoma (iCCA) presents a challenging diagnosis due to its nonspecific early clinical manifestations, often resulting in late-stage detection and high mortality. Diagnosing iCCA is further complicated by its limited...
9.
Robinson W, Stone J, Schischlik F, Gasmi B, Kelly M, Seibert C, et al.
Sci Adv
. 2024 Jul;
10(27):eadj7402.
PMID: 38959321
The study of the tumor microbiome has been garnering increased attention. We developed a computational pipeline (CSI-Microbes) for identifying microbial reads from single-cell RNA sequencing (scRNA-seq) data and for analyzing...
10.
Keggenhoff F, Castven D, Becker D, Stojkovic S, Castven J, Zimpel C, et al.
Gut
. 2024 Jun;
73(10):1712-1724.
PMID: 38857989
Objective: Intrahepatic cholangiocarcinoma (iCCA) is the second most common primary liver cancer with limited therapeutic options. mutations are among the most abundant genetic alterations in iCCA associated with poor clinical...